Singapore markets open in 4 hours 7 minutes

Traws Pharma, Inc. (0T2.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.5900-0.0200 (-3.28%)
At close: 08:06AM CEST
Full screen
Previous close0.6100
Open0.5900
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range0.5900 - 0.5900
52-week range0.5600 - 1.2700
Volume1,356
Avg. volume199
Market cap14.997M
Beta (5Y monthly)1.35
PE ratio (TTM)N/A
EPS (TTM)-0.8100
Earnings date13 May 2024 - 17 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est20.00
  • Simply Wall St.

    Traws Pharma Full Year 2023 Earnings: Beats Expectations

    Traws Pharma ( NASDAQ:TRAW ) Full Year 2023 Results Key Financial Results Net loss: US$18.9m (flat on FY 2022). US$0.90...

  • GlobeNewswire

    Traws Pharma Announces New Employee Inducement Grants

    NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards to new employees who joined Traws in connection with the recent acquisition of Trawsfynydd Therapeutics, Inc. by Onconova Therapeutics, Inc. (the “Merger”). On April 1, 2024, Traws granted restricted stock equity awards to Werner Cautreels, Iain Dukes, Nikolay Savchuk, C. David Pauza and Robert Redfield, as an inducement for each of them to accep

  • GlobeNewswire

    Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company

    Closing cash balance of approximately $28 million expected from concurrent private placement led by OrbiMed and Torrey PinesFunding expected to advance development of three potential best-in-class/class leading assets: viroksavir, a cap-dependent endonuclease inhibitor for influenza; travaltrelvir, a protease inhibitor for COVID19; and narazaciclib, a next generation CDK4/6 inhibitor for low grade endometriod endometrial cancer (LGEEC)Multiple near-term catalysts, for viroksavir and travaltrevir